Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 13/20 | 1.00 |
| ▸ | GRIA2 | P42262 | 8/20 | 1.00 |
| ▸ | GRIA1 | P42261 | 2/20 | 1.00 |
| ▸ | GRIA3 | P42263 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL959005 | 1.00 | GRIA4 (1.00) | GRIA4GRIA2GRIA1GRIA3KCNH2 | |
| SCHEMBL5877782 | 0.96 | GRIA4 (0.91) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL13255761 | 0.88 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5992693 | 0.88 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6782571 | 0.87 | GRIA4 (0.76) | GRIA4GRIA2GRIA1GRIA3KCNH2 | |
| SCHEMBL6565117 | 0.83 | GRIA4 (0.77) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5878459 | 0.82 | GRIA4 (1.00) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5878433 | 0.82 | GRIA4 (1.00) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5878300 | 0.81 | GRIA4 (0.75) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5877677 | 0.81 | GRIA4 (0.68) | GRIA4GRIA2GRIA1GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006034196-A1 | COMPOSITIONS FOR ENHANCING MEMORY AND METHODS THEREFOR | LIFELIKE BIOMATIC INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | LIFELIKE BIOMATIC, INC. (US) | 2006-03-23 | — | — | US | claimed |
| US-12064410-B2 | Compositions and methods for stimulating ventilatory and/or respiratory | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-08-20 | — | — | US | disclosed |
| EP-3316890-B1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | NEURAD LTD (IL) | 2023-09-06 | — | — | EP | disclosed |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-11 | — | — | US | disclosed |
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | VANDERKLISH PETER (US) | 2020-12-24 | — | — | US | disclosed |
| US-10543187-B2 | Compositions and methods for stimulating ventilatory and/or respiratory drive | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190231732-A1 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE | CASE WESTERN UNIVERSITY | 2019-08-01 | — | — | US | disclosed |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | NEURAD LTD. (IL) | 2019-05-21 | — | — | US | disclosed |
| US-10080732-B2 | Compositions and methods for stimulating ventilatory and/or respiratory drive | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | disclosed |
| EP-0860428-B1 | Sulphonamide derivatives | LILLY CO ELI (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2004062616-A2 | METHOD OF TREATING COGNITIVE DECLINE DUE TO SLEEP DEPRIVATION AND STRESS | CORTEX PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040054009-A1 | (BIS)sulfonamide derivatives | KNOBELSDORF JAMES ALLEN (US) | 2004-03-18 | — | — | US | disclosed |
| US-6596716-B2 | 2-propane-sulphonamide derivatives | ELI LILLY AND COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-6525099-B1 | Potentiating glutamate receptor function; psychiatric and neurological disorders | ELI LILLY AND COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-20020002158-A1 | Sulphonamide derivatives | ARNOLD MACKLIN B (US) | 2002-01-03 | — | — | US | disclosed |
| US-6303816-B1 | Sulphonamide derivatives | ELI LILLY AND COMPANY | 2001-10-16 | — | — | US | disclosed |
| WO-2000006537-A1 | N-SUBSTITUTED SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0860428-A2 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 1998-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | GRIN1, GRIN3A, GRIN2A | GRIA4 19/4885GRIA2 25/4885GRIA1 21/4885 |
| US-20020002158-A1 | Sulphonamide derivatives | GRIN2C, GRM1, GRM3 | GRIA4 20/4885GRIA2 27/4885GRIA1 17/4885 |
| US-20190231732-A1 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE | CHRM3, CTH, SLC18A3 | GRIA4 296/4885GRIA2 690/4885GRIA1 483/4885 |
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | MTNR1B, CHRM3, PER2 | GRIA4 1578/4885GRIA2 2637/4885GRIA1 2661/4885 |
| US-10080732-B2 | Compositions and methods for stimulating ventilatory and/or respiratory drive | CTH, CRH, CHRNB1 | GRIA4 291/4885GRIA2 610/4885GRIA1 426/4885 |
| US-20040054009-A1 | (BIS)sulfonamide derivatives | GRIN2A, GRIN2B, GABRE | GRIA4 14/4885GRIA2 9/4885GRIA1 15/4885 |
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | GPR119, GRIK1, GRIK3 | GRIA4 57/4885GRIA2 60/4885GRIA1 46/4885 |
| US-10543187-B2 | Compositions and methods for stimulating ventilatory and/or respiratory drive | CHRM3, CTH, SLC18A3 | GRIA4 296/4885GRIA2 690/4885GRIA1 483/4885 |
| US-12064410-B2 | Compositions and methods for stimulating ventilatory and/or respiratory | CTH, SLC25A20, CRH | GRIA4 422/4885GRIA2 780/4885GRIA1 552/4885 |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2D, GRIN2A, GRIN2C | GRIA4 14/4885GRIA2 27/4885GRIA1 26/4885 |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | MTNR1B, PDE3A, CHRM3 | GRIA4 1697/4885GRIA2 2769/4885GRIA1 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.